Comparison of efficiency and safety of conservative versus interventional management for primary spontaneous pneumothorax: A meta-analysis

Primary spontaneous pneumothorax: does size matter?

“…There is increasing evidence supporting conservative management for patients with primary spontaneous pneumothorax (PSP) regardless of size [1,2] which is reflected in the recent British Thoracic Society Guideline [3]. However, the size of the pneumothorax on radiograph likely still has an important influence on management decisions, as illustrated by a recent interactive clinical decision debate [4].…”

Management of primary spontaneous pneumothorax: Did practice change after a landmark multicentre study?

“…There is increasing evidence supporting conservative management for patients with primary spontaneous pneumo-thorax (PSP) regardless of size. 1,2 This is reflected in the most recent British Thoracic Society Guideline. 3 A sentinel collaboration between emergency clinicians and respiratory teams in 39 hospitals in Australia and New Zealand led to the publication of the Primary Spontaneous Pneumothorax study, a randomised controlled trial (RCT) which found conservative management non-inferior to intervention for re-expansion at 8 weeks for patients with medium to large PSP, with better patient centered outcomes.…”

“…There is increasing evidence supporting conservative management for patients with primary spontaneous pneumothorax (PSP) regardless of size 1,2 . This is reflected in the most recent British Thoracic Society Guideline 3 .…”

Update on the management of first episode primary spontaneous pneumothorax in an Australian hospital network

“…4 More recent guidelines and evidence instead advocate minimising active intervention. 9 They recommend conservative management where appropriate, 10 small-bore (<16Fr) intercostal catheters (ICC) over traditional largebore ICC drainage 10,11 and simple aspiration over ICC insertion. 12 Conservative management 13 and the use of an ambulatory drainage device 14 have been supported by recent landmark studies as safe, feasible and non-inferior management options in selected patients with moderate to large PSP.…”